Loading
BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
B-cell maturation antigen (TNFRSF17) is a TNF receptor family member with APRIL and BAFF as ligands that sustains plasma cell survival, and it is present on over 95% of myeloma cells with little expression elsewhere. It is targeted by CAR-T (ciltacabtagene, idecabtagene), bispecifics (teclistamab, elranatamab, linvoseltamab), and the ADC belantamab mafodotin, re-approved in 2025 on the strength of DREAMM-7/8. Soluble BCMA shed into the blood can act as a decoy, and antigen loss or downregulation is one mechanism of relapse. The open questions are how to sequence these modalities and how to manage infections in patients with prolonged plasma cell depletion. The simple version is the plasma cell survival receptor that made CAR-T and bispecifics work in multiple myeloma.
In plain words · BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
Backbone ribbon from PDB 12ES. RCSB PDB 12ES. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
BCMA is a survival receptor on plasma cells, and the target that made CAR-T and bispecifics work in multiple myeloma.
BCMA is a TNF receptor family member with APRIL and BAFF as ligands. Soluble BCMA can act as a decoy.
14 products aim at BCMA: antibody-drug conjugates, bispecific antibodies and cell therapies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Lineage antigen shared with normal B-cells and dendritic cells: HPA blood lineage group enriched at or above 25 nTPM, and 14 cell-killing or cell-finding medicines (GC012F, AZD4045, NXC-201 CAR-T and more) aim at it, so normal cells of the lineage are hit too. HPA TNFRSF17: RNA tissue enhanced (intestine 27 nTPM, lymphoid tissue 45 nTPM, stomach 1 23 nTPM); blood lineage group enriched (B-cells 125 nTPM, dendritic cells 104 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Multiple myeloma); Open Targets associates it with 1 specific cancer type at or above 0.5 (plasma cell myeloma). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas TNFRSF17 tissue; Human Protein Atlas TNFRSF17 pathology; Open Targets ENSG00000048462 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Laabi et al, EMBO J, 1992, "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma". Source.
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
Cell lines and mouse models for this target →
BCMA is a TNF receptor family member with APRIL and BAFF as ligands. Soluble BCMA can act as a decoy.
RNA: tissue enhanced (intestine 27 nTPM, lymphoid tissue 45 nTPM, stomach 1 23 nTPM), detected in many normal tissues. Blood: group enriched (B-cells 125 nTPM, dendritic cells 104 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
HPA TNFRSF17 tissue · HPA TNFRSF17 pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Multiple myeloma | >95% | Plasma-cell surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Anitocabtagene autoleucel is a BCMA CAR-T whose binder is a small synthetic D-domain protein rather than an antibody fragment, a design chosen for low immunogenicity. In heavily pretreated myeloma it produced responses in 97% of patients with mostly low-grade cytokine release syndrome and no delayed parkinsonism reported, and an FDA decision is due on 27 December 2026.
AZD0120 is a car-t cell therapy from AstraZeneca, in registered phase 3 trials for multiple myeloma.
AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.
A myeloma ADC that was withdrawn in 2022 then came back in 2025 after strong trials in earlier lines.
Ciltacabtagene autoleucel is a one-time BCMA CAR-T for myeloma that, in CARTITUDE-4, cut the risk of death by about 45% compared with standard regimens.
Elranatamab is Pfizer's BCMA bispecific, given under the skin every week then every two weeks, for myeloma after four prior lines.
Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China.
GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.
Idecabtagene vicleucel was the first myeloma CAR-T (2021) and is now approved after two prior lines based on KarMMa-3.
An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.
Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.
NXC-201 CAR-T is an experimental CAR-T cell therapy from Nexcella in phase 2 trials, aimed at BCMA.
Teclistamab was the first off-the-shelf bispecific for multiple myeloma, and is now approved after just one prior line of therapy.
Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.
CARTITUDE-4 is the first randomised trial to show that a CAR-T improves survival in myeloma, and it moved cilta-cel into second-line use (FDA approval 2024). For patients whose disease returns after first-line lenalidomide, a one-off cell therapy now competes with continuous drug combinations. Capacity, cost and the need for bridging therapy still limit who actually receives it.
The clinical result is in line with commercial BCMA CAR-T products, but the point of the paper is the manufacturing: an academic hospital produced its own CAR-T cells, infused them fresh and treated patients who would otherwise wait for a commercial slot. It is the evidence base for what Immix Biopharma now develops as NXC-201.
KarMMa-3 was the first randomised evidence that CAR-T beats conventional drugs in myeloma and led to ide-cel's approval after two prior lines. It confirmed that earlier use of CAR-T produces deeper and longer remissions than in the end-stage setting. Because responses are shorter than with cilta-cel and OS was not improved, it also sharpened debate about which BCMA CAR-T to use and when.
Elranatamab confirmed that BCMA bispecifics are a class, not a one-off, and its protocol-built dose reduction after response set a precedent for lowering the immunosuppressive burden of T-cell engagers. Patients now have two approved BCMA bispecifics and one against GPRC5D (talquetamab). Choosing between them, and sequencing them with CAR-T, remains guided by availability and toxicity profile rather than head-to-head data.
Teclistamab showed that an off-the-shelf bispecific can approach CAR-T-like response rates in late myeloma, giving patients who cannot wait for or access cell therapy a real option. It also exposed the price: prolonged T-cell engagement causes profound immunosuppression, so infection prophylaxis and immunoglobulin replacement are now routine. Less frequent dosing after response is being adopted to reduce this burden.
CARTITUDE-1 showed that a single CAR-T infusion can put late-stage myeloma into deep, multi-year remission, leading to FDA approval of cilta-cel in 2022 for heavily pretreated disease. It set the efficacy bar for BCMA-directed therapy and motivated moving CAR-T earlier (CARTITUDE-4). Late neurological toxicity and secondary malignancies remain the safety questions.
Query for this target: (TITLE:"BCMA" OR ABSTRACT:"BCMA" OR TITLE:"TNFRSF17" OR ABSTRACT:"TNFRSF17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCMA, not a curated reading list.
Shares Kelonia Therapeutics, GC012F, Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T, AZD0120 and the tag car-t-target.
Shares BCMA-directed therapy → GPRC5D-directed therapy, Multiple Myeloma Research Foundation (MMRF), Plan the second CAR-T target before the first one is lost, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg and the tag t-cell-engager-target.
Shares Cullinan Therapeutics, Philippe Moreau, Linvoseltamab, Elranatamab and the tag t-cell-engager-target.
Shares Zonghai Li, CAR-T cell therapy and the tag car-t-target.
Shares Hospital Universitario 12 de Octubre, Resistance routes: how a blocked pathway comes back, T-cell engagers (bispecific) and the tag t-cell-engager-target.
Shares CAR-T cell therapy and the tag car-t-target.
Shares Zonghai Li, CAR-T cell therapy, Antibody-drug conjugate (ADC) and the tag car-t-target.
Shares Antibody-drug conjugate (ADC) and the tag car-t-target.